

Disclosures

Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Afimmune	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants ‡ Studies of empagliflozin and its cardiovascular, renal and metabolic effects in patients with diabetes mellitus (or prediabetes) and heart failure (SUGAR-DM-HF)	Significant (>= \$5,000)	Prevention
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Hanmi Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Merck Sharp & Dohme	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Novartis Corporation	Research/Research Grants	Modest (< \$5,000)	General Cardiology
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Pfizer Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Roche Diagnostics	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (8)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Circulation	Other - Associate Editor	Modest (< \$5,000)	General Cardiology
Diabetes & Metabolic Syndrome: Clinical Research & Reviews	Other - Editorial Board Member	None (\$0)	Other
Diabetes Care	Other - Associate Editor	Modest (< \$5,000)	Other
European Society of Cardiology	Other - Member Scientific Working Group of the Cardiovascular Risk Collaboration Unit	None (\$0)	General Cardiology
European Society of Cardiology	Other - Member Task Force to develop 2023 Guidelines on Diabetes and CVD	None (\$0)	General Cardiology
International Diabetes Federation	Other - Stream Leader, Programme Committee	None (\$0)	Prevention
World Obesity Federation and World Heart Federation	Other - Member Expert Group on Obesity and Cardiovascular Disease	None (\$0)	Prevention
Worldwide CardioDiabetes	Other - Board of Directors	None (\$0)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/27/2022

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/27/2022

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 9/27/2022

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 9/27/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.